

June 20, 2014

Termination and Cash Distribution

Gentium S.p.A.

CUSIP # 37250B104

US ISIN# US37250B1044

Ratio (DRs: Underlying Shares): 1:1

Owners of American Depositary Shares (“ADSs”), each representing One (1) ordinary share of Gentium S.p.A. (the “Company”) have been previously notified that the amended Deposit Agreement between The Bank of New York Mellon (the “Depositary”) and Gentium S.p.A. was terminated effective April 13, 2014. As the period for ADR holders to cancel their ADSs has expired, BNY Mellon has accordingly sold all remaining deposited securities representing outstanding ADSs of Gentium S.p.A. (the “Gentium ADSs”) by accepting an offer by Jazz Pharmaceuticals Italy S.p.A., the controlling shareholder of the Company, to purchase those Shares at a price of \$57.00 per Share, which was the price offered in the recent cash tender offer that was made for the ADSs. Holders of Gentium ADSs are now entitled to receive the net cash proceeds from the sale of the Gentium ordinary shares on a pro-rata basis.

Effective June 26, 2014, Gentium ADS holders with accounts with financial intermediaries or with ADSs held in “uncertificated” form will have their ADSs automatically cancelled and exchanged for the cash proceeds. Holders of ADR certificates will be required, on a mandatory basis, to surrender their Gentium S.p.A. ADSs for cancellation and exchange for the cash proceeds.

The rate of distribution is as follows:

Gross Rate per ADS:	\$57.00
Less: Depositary’s Cancellation Fee per ADS:	<u>\$ 0.05</u>
Net Rate per ADS:	\$56.95

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

<i>New York</i>	<i>London</i>	<i>Hong Kong</i>
Melissa Sobolewski	Damon Rowan	Herston Powers
Ravi Davis	Vice President	Vice President
+1 212 815-2267	+44 207 964 6527	+852 2 840 9868
Adrdesk@bnymellon.com	damon.rowan@bnymellon.com	Herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliates and dealers. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.